You are here: Industry Insights > renal cell carcinoma

News List

NICE recommends avelumab and axitinib to treat renal cell carcinoma europeanpharmaceuticalreview
August 03, 2020
Bavencio (avelumab) and Inlyta (axitinib) are recommended by NICE for the treatment of advanced renal cell carcinoma, available on the Cancer Drugs Fund.
Aravive Receives IND Clearance for AVB-500 Trial for Clear Cell Renal Cell Carcinoma americanpharmaceuticalreview
January 17, 2020
Aravive announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for investigation of the company’s lead candidate, AVB-500, for the treatment of clear cell renal cell carcinoma (ccRCC
Tivozanib Bests Sorafenib in Metastatic Renal Cell Carcinoma drugs
December 27, 2019
Among patients with metastatic renal cell carcinoma, progression-free survival was longer in those receiving tivozanib versus sorafenib as third- or fourth-line therapy ...
Former Aveo CFO found guilty of misleading investors about prospects for cancer drug fiercepharma
December 10, 2018
The SEC’s two-year battle with Aveo Pharmaceuticals over the company’s embattled kidney cancer drug tivozanib has come to a close with a jury verdict against its former chief financial officer, David Johnston.
Roche withdraws Tecentriq combo application in first-line renal cell carcinoma pharmafile
November 20, 2018
The EMA has revealed that Roche has chosen to withdraw its marketing application for immunotherapy Tecentriq (atezolizumab) in combination with Genentech’s Avastin (bevacizumab) as a first-line treatment for renal cell carcinoma (RCC) due to insufficient
AVEO Oncology Announces Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma americanpharmaceuticalreview
June 22, 2017
AVEO Oncology announced the company’s pivotal TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC) has reached its enrollment target of 322